- Home
- MRSN vs WRN Comparison
MRSN vs WRN Comparison
Compare MRSN & WRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- WRN
- Stock Information
- Founded
- MRSN 2001
- WRN 2006
- Country
- MRSN United States
- WRN Canada
- Employees
- MRSN N/A
- WRN N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- WRN Metal Mining
- Sector
- MRSN Health Care
- WRN Basic Materials
- Exchange
- MRSN Nasdaq
- WRN Nasdaq
- Market Cap
- MRSN 252.0M
- WRN 237.4M
- IPO Year
- MRSN 2017
- WRN N/A
- Fundamental
- Price
- MRSN $1.86
- WRN $1.04
- Analyst Decision
- MRSN Buy
- WRN Strong Buy
- Analyst Count
- MRSN 6
- WRN 1
- Target Price
- MRSN $6.00
- WRN $4.25
- AVG Volume (30 Days)
- MRSN 1.1M
- WRN 161.3K
- Earning Date
- MRSN 11-13-2024
- WRN 11-07-2024
- Dividend Yield
- MRSN N/A
- WRN N/A
- EPS Growth
- MRSN N/A
- WRN N/A
- EPS
- MRSN N/A
- WRN N/A
- Revenue
- MRSN $34,837,000.00
- WRN N/A
- Revenue This Year
- MRSN N/A
- WRN N/A
- Revenue Next Year
- MRSN N/A
- WRN N/A
- P/E Ratio
- MRSN N/A
- WRN N/A
- Revenue Growth
- MRSN N/A
- WRN N/A
- 52 Week Low
- MRSN $1.22
- WRN $0.95
- 52 Week High
- MRSN $6.28
- WRN $1.66
- Technical
- Relative Strength Index (RSI)
- MRSN 42.16
- WRN 42.66
- Support Level
- MRSN $1.93
- WRN $1.03
- Resistance Level
- MRSN $2.81
- WRN $1.14
- Average True Range (ATR)
- MRSN 0.24
- WRN 0.04
- MACD
- MRSN -0.05
- WRN -0.00
- Stochastic Oscillator
- MRSN 7.79
- WRN 28.13
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).